Role of L arginine in treatment of osteoporosis

Abstract

AIM : Osteoporosis is a systemic skeletal disorder characterized by low

bone mass and microarchitectural deterioration of bone tissue. Today, an increasing number of medications are available to treat osteoporosis and reduce fracture risks. However, these agents are costly and all have adverse effects, such as upper gastrointestinal irritation and ulceration, constipation, and enhanced arterial and venous thrombosis, etc . The aim of the present study is to study the role of L arginine  in treatment of osteoporosis

METHOD: Total of 180 osteoporotic female with DEXA T‐score <‐2.5 and vitamin D level >20ng/ml  were selected and divided in to two study groups , 90 patients in each group. The average BMD pre therapy in group A was compared with the post therapy, Similarly in group B pre therapy mean BMD was compared with the post therapy mean BMD and the percentage increased was calculated. Finally the percentage increased in group A was compared with the group B and the result was analysed

RESULT:  On  comparing our test drug L–arginine with the standard drug zoledronic acid IV infusion ,we found that there is no difference in result with the increase in BMD in the two groups. The drug L‐arginine is as good as inj. zoledronic acid in the treatment of osteoporosis

CONCLUSION: The Zoledronic acid iv infusion and the L‐arginine both increase the bone mineral density of the LS spine and both are equivalent in efficacy and both can be conveniently be used in the treatment of osteoporosis in the peri and post menopausal osteoporotic females